Janux Therapeutics, Inc.·4

Jan 2, 9:00 PM ET

Meyer Andrew Hollman 4

4 · Janux Therapeutics, Inc. · Filed Jan 2, 2026

Insider Transaction Report

Form 4
Period: 2026-01-02
Meyer Andrew Hollman
Chief Business Officer
Transactions
  • Sale

    Common Stock

    2026-01-02$13.73/sh1,879$25,79983,095 total
Footnotes (1)
  • [F1]The shares were automatically sold to cover tax withholding obligations associated with the vesting of restricted stock units.

Documents

1 file
  • 4
    form4-01022026_090112.xmlPrimary